In the honeymoon period in T1DM, it is possible to use C-peptide to observe whether a possible worsening in glycemic control is due to a decline in insulin secretion or, for example, poor adherence to medication.26 Ho et al. found no significant decrease in HbA1c with the use of prebiotics during the treatment period, but there was a preservation of C-peptide in the prebiotic group, proving to be a promising clinical marker of the prolongation of the residual function of pancreatic beta cells. Here, INS is linked to type 1 diabetes mellitus.